ArticleEJHaem2026
Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
64007957MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
TECLIMMY1001-P3: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With an additional year of follow-up compared with the previous report, this study presents the 27.2-month efficacy and safety outcomes of the MajesTEC-1 China cohort. Methods: A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE-RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly, with potential transition to every 2 weeks in sustained responders. Results: Overall response rate (ORR) was 76.9%, with all responders achieving a very good partial response or better (≥ VGPR), and 75% achieving a complete response or better (≥ CR). Median progression‑free survival (PFS) was 25.1 months, while median duration of response (DOR) and overall survival (OS) were not reached. Among patients achieving ≥ CR, estimated 30‑month DOR, PFS, and OS rates were favorable at 80.0%, 80.0%, and 93.3%, respectively. Patients with poor prognostic features achieved ORRs comparable to overall population, and their DOR was generally consistent. Quality-of-life assessments showed improvements from baseline in global health status, physical functioning, fatigue, and pain. Safety profile was consistent with previous publication. Incidence of new-onset Grade ≥ 3 infections decreased over time, which was consistent with the timing of transition to biweekly dosing and may be related to immunoglobulin use. Conclusion: These findings support teclistamab as a standard-of-care for patients with TCE-RRMM in China. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03145181/NCT04557098.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.